Mexazolam
 |
|
|---|---|
 |
|
| Systematic (IUPAC) name | |
| 10-chloro- 11b-(2-chlorophenyl)- 3-methyl- 2,3,7,11b-tetrahydro [1,3]oxazolo [3,2-d] [1,4]benzodiazepin- 6(5H)-one | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | Schedule IV(US) |
| Routes | Oral |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic |
| Half-life | ? |
| Excretion | Renal |
| Identifiers | |
| ATC code | None |
| PubChem | CID 4177 |
| ChemSpider | 4033  |
| UNII | S5969B6237 |
| KEGG | D01316 |
| Synonyms | 13-chloro- 2-(2-chlorophenyl)- 5-methyl- 3-oxa- 6,9-diazatricyclo[8.4.0.02,6] tetradeca- 1(10),11,13-trien- 8-one |
| Chemical data | |
| Formula | C18H16Cl2N2O2 |
| Mol. mass | 363.237 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
Mexazolam[1] (marketed under the trade names Melex and Sedoxil)[2] is a drug which is a benzodiazepine derivative.[3] Mexazolam has been trialed for anxiety and was found to be effective in alleviating anxiety at one week follow-up, however, after three weeks of therapy mexazolam had lost its therapeutic anxiolytic properties becoming no more effective than placebo, presumably due to benzodiazepine tolerance.[4] Mexazolam is metabolised via the CYP3A4 pathway. HMG-CoA reductase inhibitors including simvastatin, simvastatin acid, lovastatin, fluvastatin, atorvastatin and cerivastatin inhibit the metabolism of mexazolam,[5] but not the HMG-CoA reductase inhibitor pravastatin.[6][7]
[edit] See also
[edit] References
- ^ DE Patent 1954065
- ^ "Benzodiazepine Names". non-benzodiazepines.org.uk. http://www.non-benzodiazepines.org.uk/benzodiazepine-names.html. Retrieved 2009-04-05.
- ^ Kurono, Y; Kamiya, K; Kuwayama, T; Jinno, Y; Yashiro, T; Ikeda, K (1987). "Kinetics and mechanism of the acid-base equilibrium of mexazolam and comparison with those of other commercial benzodiazepinooxazole drugs". Chemical & pharmaceutical bulletin 35 (9): 3831–7. PMID 2893667.
- ^ Ferreira, L; Figueira, ML; Bessa-Peixoto, A; Marieiro, A; Albuquerque, R; Paz, C; Cerqueira, A; Damião, P et al (2003). "Psychomotor and anxiolytic effects of mexazolam in patients with generalised anxiety disorder.". Clinical drug investigation 23 (4): 235–43. doi:10.2165/00044011-200323040-00003. PMID 17535036.
- ^ Mc Donnell, CG; Harte, S; O'driscoll, J; O'loughlin, C; Van Pelt, FN; Shorten, GD (2003). "The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam". Anaesthesia 58 (9): 899–904. doi:10.1046/j.1365-2044.2003.03339.x. PMID 12911366.
- ^ Ishigami, M; Takasaki, W; Ikeda, T; Komai, T; Ito, K; Sugiyama, Y (2002). "Sex difference in inhibition of in vitro mexazolam metabolism by various 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors in rat liver microsomes.". Drug metabolism and disposition: the biological fate of chemicals 30 (8): 904–10. doi:10.1124/dmd.30.8.904. PMID 12124308. http://dmd.aspetjournals.org/cgi/content/full/30/8/904.
- ^ Ishigami, Michi; Honda, Tomoyo; Takasaki, Wataru; Ikeda, Toshihiko; Komai, Toru; Ito, Kiyomi; Sugiyama, Yuichi (2001). "A Comparison of the Effects of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors on the CYP3A4-Dependent Oxidation of Mexazolam in Vitro". Drug Metabolism and Disposition 29 (3): 282–8. PMID 11181496. http://dmd.aspetjournals.org/cgi/content/full/29/3/282.
 |
This sedative-related article is a stub. You can help Wikipedia by expanding it. |
